Equibles does not estimate personal net worth.
Get an email with a short summary when Avax One Technology Ltd. publishes a filing, an earnings call transcript or a press release.
Get AVX alertsJolie Kahn is recorded as CEO at Avax One Technology Ltd. (AVX) since June 4, 2024, Board Member at Avax One Technology Ltd. (AVX) since January 1, 2024 and CFO at Ocean Biomedical, Inc. (OCEA) since March 1, 2024. The newest filing on record that lists Jolie Kahn as Board Member at Avax One Technology Ltd. (AVX) is dated April 23, 2026. Jolie Kahn was last confirmed as Board Member at Portsmouth Square Inc (PRSI) in a filing dated April 8, 2025. Earlier roles on record: CFO at Glucotrack, Inc. (GCTK) until October 6, 2023. Avax One Technology Ltd. reported in an 8-K filed July 6, 2026 that Jolie Kahn resigned as Chief Executive Officer, effective July 3, 2026. Ocean Biomedical, Inc. reported in an 8-K filed August 5, 2025 that Jolie Kahn resigned as CFO, effective August 5, 2025. Avax One Technology Ltd. reported in an 8-K filed June 10, 2024 that Jolie Kahn was appointed Chief Executive Officer, effective June 4, 2024. Equibles holds 6 filed executive changes naming Jolie Kahn; each is listed under recent activity with its source filing. The proxy statement of Glucotrack, Inc. reports total compensation of $120,000 for Jolie Kahn in fiscal 2022, including a base salary of $120,000. Disclosed compensation is on record for 2 fiscal years. Jolie Kahn has spoken on 1 earnings call across 1 company, most recently for Avax One Technology Ltd. on March 31, 2026. Avax One Technology Ltd. is classified in the Software - Infrastructure industry within the Technology sector. Ocean Biomedical, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Avax One Technology Ltd. includes Ingo Mueller (CEO), Peter Wylie Jr. (CEO), Richard Wong (CEO) and 7 others.
“On July 3, 2026 (the "Effective Date"), by mutual agreement, Jolie Kahn departed from her role as Chief Executive Officer of AVAX One Technology Ltd. (the "Company"), effective as of the Effective Date.”
“On August 5, 2025, Jolie Kahn resigned as CFO of the Company, which resignation was effective on that date.”
“I'm pleased to welcome you all to our first earnings conference call, Zavex One Technology. The fourth quarter of 2025 was a transformational period for AVAX-1, as we completed our transition to an avalanche-focused digital asset treasury strategy.”
2024-06-04–present
2024-03-01–present
SEC 8-K
2024-02-10–present
2024-01-01–present
Last confirmed April 23, 2026
2024-03-01–2025-08-05
Start not stated–2025-04-08
Last confirmed by a filing; no departure on record
Start not stated–2023-10-06
Start not stated–2025-08-05
Start not stated–2026-07-03
Software - Infrastructure · Technology
CEO, Board Member
2024-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Glucotrack, Inc. (GCTK) | Chief Financial Officer | $120,000 | $120,000 |
| 2021 | Glucotrack, Inc. (GCTK) | Chief Financial Officer | $120,000 | $120,000 |
